Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Receives CE Mark for TB MDx

NEW YORK (GenomeWeb) – Abbott announced on Wednesday it received CE marking for a new molecular diagnostic test for detecting Mycobacterium tuberculosis.

The new test runs on Abbott's m2000 molecular diagnostic platform, and can be consolidated with the company's HIV-1 detection assay. An MTB inactivation step is included with the MTB test procedure to reduce the risk of airborne infection during the handing of sample material, Abbott said.

The World Health Organization estimates that in 2012, there were 8.6 million people globally who developed TB. Of these, 1.1 million were also HIV-positive, and a molecular diagnostic is needed by clinicians to prevent the transmission of TB and HIV, said Gavin Cloherty, director of global scientific affairs, infectious diseases, and molecular diagnostics for Abbott.

"TB is curable and with expanded access to molecular diagnostics technologies there is great potential to save lives in resource-limited areas," he said in a statement. Abbott noted that 75 percent of TB-HIV infections occur in high-burden areas, such as Africa.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.